Categories: GovTechDevelopmentCareBuildingBioTechActiveWebsiteResearchLifeHealthTech
iTeos Therapeutics is a private biotechnology company targeting metabolism of the tumor microenvironment to develop small molecule immunomodulators for cancer treatments. iTeos is building its activities upon the unparalleled expertise of the Ludwig Cancer Research (LICR) – a world-class Research Institute in the fields of tumor immunology, therapeutic cancer vaccines, cancer biology and translational medicine in cancer.
iTeos endeavours to develop small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standard of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints (e.g. anti-CTLA4, anti-PD1 and anti-PDL1 antibodies).
Based in Gosselies, Belgium iTeos is a private company launched in 2012 as a spin-off of the Ludwig Cancer Research (LICR) and the de Duve Institute at the Université catholique de Louvain. iTeos raised €9,1M in 2012 from private investors, including LICR, Life Sciences Research Partners, Vives II, Hunza Ventures SCA, several high net worth individuals and from a Walloon government grant.
Website
Location: United States, Massachusetts, Cambridge
Investors 8
Funding Rounds 4
Date | Series | Amount | Investors |
01.04.2020 | - | $125M | - |
30.01.2020 | Grant | $16.64M | - |
21.06.2018 | Series B | $75M | MPM Capita... |
07.12.2015 | Grant | $3.19M | - |
Mentions in press and media 17
Date | Title | Description | Source |
09.03.2024 | iTeos: A Financial Success Story | iTeos, a biotechnology company, recently released its financial results for the fourth quarter and f... | parsers.vc... |
07.03.2024 | iTeos fait le point sur ses activités et publie ses résultat... | - | globenewsw... |
06.03.2024 | La spécialiste en oncologie Jill DeSimone rejoint le Conseil... | - | globenewsw... |
06.03.2024 | iTeos Appoints Oncology Veteran Jill DeSimone to Its Board o... | - | globenewsw... |
06.03.2024 | iTeos Reports Fourth Quarter and Full Year 2023 Financial Re... | - | globenewsw... |
05.03.2024 | iTeos to Highlight Preclinical Data on First-In-Class EOS-98... | - | globenewsw... |
05.03.2024 | iTeos présentera les données précliniques d’EOS-984, premier... | - | globenewsw... |
01.04.2020 | iTeos Therapeutics Closes $125M Series B2 |
CAMBRIDGE, MA, iTeos Therapeutics announced the closing of an oversubscribed $125M Series B2 finan... | vcnewsdail... |
01.04.2020 | iTeos Therapeutics Raises $125M in Series B2 Funding | iTeos Therapeutics Inc., a Cambridge, MA and Gosselies, Belgium – based clinical-stage biotechnology... | finsmes.co... |
01.04.2020 | iTeos Therapeutics Closes $125 Million Series B2 Financing | - | mpmcapital... |
30.01.2020 | iTeos Therapeutics Awarded €15 Million in Non-Dilutive Fundi... | - | mpmcapital... |
21.06.2018 | iTeos Therapeutics Closes $75M Series B Financing | iTeos Therapeutics SA, a Gosselies, Belgium – based biotechnology company developing novel cancer im... | finsmes.co... |
21.06.2018 | Term Sheet — Thursday, June 21 | GLOBAL DOMINATION
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see... | fortune.co... |
20.06.2018 | ITeos raises $75M to trial immuno-oncology drugs | iTeos Therapeutics has raised $75 million (€64 million) to take two immuno-oncology assets into the ... | fiercebiot... |
20.06.2018 | ITeos raises $75M to trial immuno-oncology drugs | iTeos Therapeutics has raised $75 million (€64 million) to take two immuno-oncology assets into the ... | fiercebiot... |
20.06.2018 | MPM Leads $75 Million Series B Financing of iTeos Therapeuti... | - | mpmcapital... |
07.12.2015 | iTeos Therapeutics Receives €2.94M Grant | iTeos Therapeutics SA, a Gosselies, Belgium-based drug discovery company for immunomodulators, recei... | finsmes.co... |
Show more
Reviews 0